INTRANASALLY ADMINISTERED RUBELLA VACCINE
The RA27/3 strain of rubella virus, which is an effective attenuated strain when given subcutaneously, is also immunogenic when given intranasally. Given in a dose of 1000 plaque-forming units (P.F.U.) in the form of nose drops, the virus produced antibodies in 93% of subjects (mainly children); a d...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1968-01, Vol.292 (7575), p.934-937 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 937 |
|---|---|
| container_issue | 7575 |
| container_start_page | 934 |
| container_title | The Lancet (British edition) |
| container_volume | 292 |
| creator | Plotkin, S.A. Ingalls, T.H. Farquhar, J.D. Katz, Michael |
| description | The RA27/3 strain of rubella virus, which is an effective attenuated strain when given subcutaneously, is also immunogenic when given intranasally. Given in a dose of 1000 plaque-forming units (P.F.U.) in the form of nose drops, the virus produced antibodies in 93% of subjects (mainly children); a dose of 100 P.F.U. immunised 50% of subjects. Clinical reaction was absent except for occasional lymphadenopathy. Nasopharyngeal virus excretion was sporadic, and there was no spread to contacts. Antibody responses to intranasal vaccination were equivalent to those obtained after subcutaneous inoculation. |
| doi_str_mv | 10.1016/S0140-6736(68)91166-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_84961342</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673668911665</els_id><sourcerecordid>84961342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-b44bb684e5f85e148597d12d3d93e6490f27c365cc2959e778088e4b044f191a3</originalsourceid><addsrcrecordid>eNqFkEtLw0AUhQdRaq3-hEJXYhfRmeTOayUxjRqIEfoQXQ3J5AYifZlpBf-96QO3ru7ifOceziGkz-gto0zcTSgD6gkZiBuhhpoxITx-QroMJHgc5Psp6f4h5-TCuU9KKQjKO6QDTApfsC4ZJtl0HGbhJEzTj0E4ekmyZDKNx_FoMJ49xGkaDt7CKEqy-JKcVfnc4dXx9sjsMZ5Gz176-pREYerZQNCNVwAUhVCAvFIcGSiuZcn8Mih1gAI0rXzZktxaX3ONUiqqFEJBASqmWR70yPXh77pZfW3Rbcyidhbn83yJq60zCrRgAfgtyA-gbVbONViZdVMv8ubHMGp2E5n9RGbX3whl9hMZ3vr6x4BtscDyz3XcpNXvDzq2Lb9rbIyzNS4tlnWDdmPKVf1Pwi909G-v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>84961342</pqid></control><display><type>article</type><title>INTRANASALLY ADMINISTERED RUBELLA VACCINE</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Plotkin, S.A. ; Ingalls, T.H. ; Farquhar, J.D. ; Katz, Michael</creator><creatorcontrib>Plotkin, S.A. ; Ingalls, T.H. ; Farquhar, J.D. ; Katz, Michael</creatorcontrib><description>The RA27/3 strain of rubella virus, which is an effective attenuated strain when given subcutaneously, is also immunogenic when given intranasally. Given in a dose of 1000 plaque-forming units (P.F.U.) in the form of nose drops, the virus produced antibodies in 93% of subjects (mainly children); a dose of 100 P.F.U. immunised 50% of subjects. Clinical reaction was absent except for occasional lymphadenopathy. Nasopharyngeal virus excretion was sporadic, and there was no spread to contacts. Antibody responses to intranasal vaccination were equivalent to those obtained after subcutaneous inoculation.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(68)91166-5</identifier><identifier>PMID: 4176261</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Antibody Formation ; Child ; Child, Preschool ; Humans ; Injections, Subcutaneous ; Methods ; Nasopharynx - microbiology ; Rubella virus - immunology ; Rubella virus - isolation & purification ; Viral Vaccines - administration & dosage</subject><ispartof>The Lancet (British edition), 1968-01, Vol.292 (7575), p.934-937</ispartof><rights>1968</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-b44bb684e5f85e148597d12d3d93e6490f27c365cc2959e778088e4b044f191a3</citedby><cites>FETCH-LOGICAL-c360t-b44bb684e5f85e148597d12d3d93e6490f27c365cc2959e778088e4b044f191a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(68)91166-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4176261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plotkin, S.A.</creatorcontrib><creatorcontrib>Ingalls, T.H.</creatorcontrib><creatorcontrib>Farquhar, J.D.</creatorcontrib><creatorcontrib>Katz, Michael</creatorcontrib><title>INTRANASALLY ADMINISTERED RUBELLA VACCINE</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The RA27/3 strain of rubella virus, which is an effective attenuated strain when given subcutaneously, is also immunogenic when given intranasally. Given in a dose of 1000 plaque-forming units (P.F.U.) in the form of nose drops, the virus produced antibodies in 93% of subjects (mainly children); a dose of 100 P.F.U. immunised 50% of subjects. Clinical reaction was absent except for occasional lymphadenopathy. Nasopharyngeal virus excretion was sporadic, and there was no spread to contacts. Antibody responses to intranasal vaccination were equivalent to those obtained after subcutaneous inoculation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibody Formation</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Methods</subject><subject>Nasopharynx - microbiology</subject><subject>Rubella virus - immunology</subject><subject>Rubella virus - isolation & purification</subject><subject>Viral Vaccines - administration & dosage</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1968</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLw0AUhQdRaq3-hEJXYhfRmeTOayUxjRqIEfoQXQ3J5AYifZlpBf-96QO3ru7ifOceziGkz-gto0zcTSgD6gkZiBuhhpoxITx-QroMJHgc5Psp6f4h5-TCuU9KKQjKO6QDTApfsC4ZJtl0HGbhJEzTj0E4ekmyZDKNx_FoMJ49xGkaDt7CKEqy-JKcVfnc4dXx9sjsMZ5Gz176-pREYerZQNCNVwAUhVCAvFIcGSiuZcn8Mih1gAI0rXzZktxaX3ONUiqqFEJBASqmWR70yPXh77pZfW3Rbcyidhbn83yJq60zCrRgAfgtyA-gbVbONViZdVMv8ubHMGp2E5n9RGbX3whl9hMZ3vr6x4BtscDyz3XcpNXvDzq2Lb9rbIyzNS4tlnWDdmPKVf1Pwi909G-v</recordid><startdate>19680101</startdate><enddate>19680101</enddate><creator>Plotkin, S.A.</creator><creator>Ingalls, T.H.</creator><creator>Farquhar, J.D.</creator><creator>Katz, Michael</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19680101</creationdate><title>INTRANASALLY ADMINISTERED RUBELLA VACCINE</title><author>Plotkin, S.A. ; Ingalls, T.H. ; Farquhar, J.D. ; Katz, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-b44bb684e5f85e148597d12d3d93e6490f27c365cc2959e778088e4b044f191a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1968</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibody Formation</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Methods</topic><topic>Nasopharynx - microbiology</topic><topic>Rubella virus - immunology</topic><topic>Rubella virus - isolation & purification</topic><topic>Viral Vaccines - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plotkin, S.A.</creatorcontrib><creatorcontrib>Ingalls, T.H.</creatorcontrib><creatorcontrib>Farquhar, J.D.</creatorcontrib><creatorcontrib>Katz, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plotkin, S.A.</au><au>Ingalls, T.H.</au><au>Farquhar, J.D.</au><au>Katz, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>INTRANASALLY ADMINISTERED RUBELLA VACCINE</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1968-01-01</date><risdate>1968</risdate><volume>292</volume><issue>7575</issue><spage>934</spage><epage>937</epage><pages>934-937</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>The RA27/3 strain of rubella virus, which is an effective attenuated strain when given subcutaneously, is also immunogenic when given intranasally. Given in a dose of 1000 plaque-forming units (P.F.U.) in the form of nose drops, the virus produced antibodies in 93% of subjects (mainly children); a dose of 100 P.F.U. immunised 50% of subjects. Clinical reaction was absent except for occasional lymphadenopathy. Nasopharyngeal virus excretion was sporadic, and there was no spread to contacts. Antibody responses to intranasal vaccination were equivalent to those obtained after subcutaneous inoculation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>4176261</pmid><doi>10.1016/S0140-6736(68)91166-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1968-01, Vol.292 (7575), p.934-937 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_84961342 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Antibody Formation Child Child, Preschool Humans Injections, Subcutaneous Methods Nasopharynx - microbiology Rubella virus - immunology Rubella virus - isolation & purification Viral Vaccines - administration & dosage |
| title | INTRANASALLY ADMINISTERED RUBELLA VACCINE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A05%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=INTRANASALLY%20ADMINISTERED%20RUBELLA%20VACCINE&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Plotkin,%20S.A.&rft.date=1968-01-01&rft.volume=292&rft.issue=7575&rft.spage=934&rft.epage=937&rft.pages=934-937&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(68)91166-5&rft_dat=%3Cproquest_cross%3E84961342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=84961342&rft_id=info:pmid/4176261&rft_els_id=S0140673668911665&rfr_iscdi=true |